{
  "abstract": "Background/aim\n\nS-1 monotherapy is used for a subset of patients with advanced non-small-cell lung cancer (NSCLC); however, predictors of prolonged treatment and survival remain unclear. The aim of this study was to investigate clinical factors associated with extended S-1 treatment and clinical outcomes in patients with advanced NSCLC.Patients and methods\n\nWe retrospectively reviewed the data of 32 patients with stage IIIB/IV or recurrent NSCLC who received S-1 monotherapy at Kanazawa Medical University Hospital from January 2015 and December 2025. Patients were classified into a long-term treatment group (≥90 days, n=13) or a short-term treatment group (<90 days, n=19).Results\n\nOverall, the median duration of treatment was 103.4 days (range=12-342 days), the objective response rate was 12.5%, and the disease control rate was 46.9%. Baseline characteristics were generally comparable between the two groups. The study endpoints, including disease control rate and overall survival, were significantly improved in the long-term treatment group. The disease control rate was significantly higher for the long-term group than for the short-term group (84.6% vs. 21.1%, p=0.001). The median overall survival was also significantly longer for the long-term group (1,529 vs. 733 days, p=0.003). Treatment-related adverse events were mild: no grade ≥3 toxicities or treatment-related deaths were observed.Conclusion\n\nProlonged S-1 treatment was associated with improved disease control and longer overall survival in patients with advanced NSCLC. These findings suggest that disease stabilization, rather than tumor shrinkage, may be a key determinant of the long-term benefit of S-1 monotherapy.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Respiratory Medicine, Kanazawa Medical University, Uchinada-machi, Ishikawa, Japan."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yutaka Takahara"
    },
    {
      "affs": [
        0
      ],
      "name": "Ryudai Abe"
    },
    {
      "affs": [
        0
      ],
      "name": "Sumito Nagae"
    },
    {
      "affs": [
        0
      ],
      "name": "Takuya Tanaka"
    },
    {
      "affs": [
        0
      ],
      "name": "Yoko Ishige"
    },
    {
      "affs": [
        0
      ],
      "name": "Ikuyo Shionoya"
    },
    {
      "affs": [
        0
      ],
      "name": "Kouichi Yamamura"
    },
    {
      "affs": [
        0
      ],
      "name": "Masaharu Iguchi"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/311n6hqp686r5.bib",
  "cited_by": 0,
  "doi": "10.21873/cdp.10601",
  "fulltext_url": "https://europepmc.org/articles/PMC13724022",
  "id": "311n6hqp686r5",
  "issns": [
    "2732-7787"
  ],
  "landing_url": "https://europepmc.org/article/MED/42968828",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7225090319",
  "pdf_url": "https://europepmc.org/articles/PMC13724022?pdf=render",
  "pmcid": "PMC13724022",
  "pmid": "42968828",
  "published": "2026-11-01",
  "publisher": "International Institute of Anticancer Research",
  "ris": "https://research.draconitic.com/paper/311n6hqp686r5.ris",
  "sources": [
    {
      "first_seen": "2026-11-03T15:20:53Z",
      "native_id": "MED:42968828",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42968828"
    },
    {
      "first_seen": "2026-11-04T12:22:33Z",
      "native_id": "PMC13724022",
      "source": "pmc",
      "url": "https://doi.org/10.21873/cdp.10601"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Treatments and Mutations",
      "subfield": "general"
    }
  ],
  "title": "Association Between S-1 Treatment Duration and Disease Control in Advanced Non-small-cell Lung Cancer.",
  "title_text": "Association Between S-1 Treatment Duration and Disease Control in Advanced Non-small-cell Lung Cancer.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-05T12:20:44Z",
  "url": "https://research.draconitic.com/paper/311n6hqp686r5",
  "venue": "Cancer diagnosis & prognosis",
  "versions": []
}